gastroenterology
(5)
Jeffery Ryan
Jeffery Ryan is the co-founder, president, and CEO of Interscope, Inc., a Massachusetts medical device company behind the EndoRotor System, a mechanical, non-thermal tool for interventional gastroenterology and pulmonology. A former U.S. Air Force captain who moved into medical device sales at Medtronic and Smith & Nephew, Ryan launched Interscope in 2013 with physician co-founder Dr. Ramon A. Franco, Jr., steering the EndoRotor from concept to FDA clearances and a 2020 distribution partnership with Micro-Tech Endoscopy.
Sheri Rudberg
Sheri Rudberg is the co-founder and CEO of WovenX Health, a Chicago-based digital health company that pairs specialty-trained virtual care teams with an AI-native platform to fix the brutal wait times patients face for gastroenterology and other specialty care. A lawyer and operator by training - Georgetown Law, a Northwestern MBA, and years running a $100M business at Hillrom - she started the company (originally Telebelly Health) after watching her own family struggle to get specialist appointments. WovenX partners with brick-and-mortar practices and health systems rather than competing with them, aiming to turn months-long backlogs into care delivered in minutes.
Scott Schorer
Scott Schorer is CEO and Chairman of G-Tech Medical, a Mountain View startup building GutTracker, a wireless dermal-patch system that reads the body's gut signals at home over days instead of hours. A Dartmouth-trained engineer and former 82nd Airborne infantry officer, he has spent two decades founding, turning around and selling medical-device companies, raising more than $120 million in equity and earning his name on six patents along the way.
Asit Parikh
Asit Parikh is a physician-scientist turned biotech chief executive who runs MOMA Therapeutics, a Cambridge, Massachusetts company built around the idea of systematically drugging molecular machines - the highly dynamic, shape-shifting proteins that most drug hunters avoid. An MD-PhD trained at Vanderbilt with clinical roots in gastroenterology, he spent two decades at Millennium and Takeda, where he helped steer the inflammatory bowel disease drug vedolizumab (Entyvio) from research to global blockbuster, before taking the CEO seat at MOMA in 2021. He has since raised a $150 million Series B and signed a roughly $2 billion partnership with Roche to push precision cancer medicines toward the clinic.
Steven Basta
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.